Evidence map›Paper›PMID 40014623›Full record

ArticlePloS one2025

Exploratory algorithms to devise multi-epitope subunit vaccine by examining HIV-1 envelope glycoprotein: An immunoinformatics and viroinformatics approach.

Saurav Kumar Mishra, Kanishka Sithira Senathilake, Neeraj Kumar, Chirag N Patel, Mohammad Borhan Uddin, Taha Alqahtani, Ali Alqahtani, Hanan M Alharbi, John J Georrge

RetractedAbstract readRetracted Publication
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Saurav Kumar MishraDepartment of Bioinformatics, University of North Bengal, Darjeeling, West Bengal, India.
Kanishka Sithira SenathilakeInstitute of Biochemistry, Molecular Biology and Biotechnology, University of Colombo, Colombo, Sri Lanka.
Neeraj KumarDepartment of Pharmaceutical Chemistry Bhupal Nobles, College of Pharmacy, Udaipur, Rajasthan, India.
Chirag N PatelDepartment of Botany, Bioinformatics and Climate Change Impacts Management, School of Science, Gujarat University, Ahmedabad, India.
Mohammad Borhan UddinComputational Biology Research Laboratory, Department of Pharmacy, Faculty of Health and Life Sciences, Daffodil International University, Dhaka, Bangladesh.ORCID 0009-0005-1420-5634
Taha AlqahtaniDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Ali AlqahtaniDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.
Hanan M AlharbiDepartment of Pharmaceutical Sciences, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
John J GeorrgeDepartment of Bioinformatics, University of North Bengal, Darjeeling, West Bengal, India.ORCID 0000-0002-9858-6112

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acquired immune deficiency syndrome (AIDS), a widespread pandemic and severe health issue, is triggered by the human immunodeficiency virus (HIV); there is no specific vaccine to cure this infection, and the situation is worsening. Therefore, this research sought to develop a vaccine with multiple epitopes against this infection targeting envelope glycoprotein (vital in host-cell interaction) through the immunoinformatics and viroinformatics approach. We identified one B-cell, eight MHC-I, and four MHC-II epitopes on its immunogen-assisted screening. In addition, these putative epitopes were conjoined concurrently using a specific linker (EAAAK, KK, GPGPG), including an adjuvant and a His-Tag at the N and C terminal, respectively, to augment its immune reaction. The final constructed entity consists of 284 amino acids; immunological evaluation demonstrated that the developed vaccine possesses antigenic features with a value of 0.6222, is non-allergenic, and has prospective physiochemical characteristics. The secondary and tertiary structures were anticipated, and their quality has been evaluated. Further, docking analysis between vaccines with TLR3 shows a strong molecular interaction with a -20.0 kcal/mol binding energy, and the stability was analysed through the MD simulation (100ns). Moreover, the designed vaccine expression and immune response were analysed, and a high vaccine expression level was found (pET28a (+)) and robust immune response followed by codon adaptation index value 0.94, 58.36% GC content, and the generation of IgM +  IgG, cytokines and interleukin. Based on overall investigation, the developed vaccine stimulates a robust immune response. Nevertheless, laboratory analysis is needed to confirm the protective potency of the vaccine.

Indexed as

AIDS VaccinesAlgorithmsenv Gene Products, Human Immunodeficiency VirusEpitopesHIV-1Vaccines, SubunitComputational BiologyEpitopes, B-LymphocyteHumansImmunoinformaticsMolecular Docking SimulationAIDS Vaccinesenv Gene Products, Human Immunodeficiency VirusEpitopesEpitopes, B-LymphocyteVaccines, Subunit

Identifiers

PMID40014623
PMCPMC11867397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.